| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Cizzle Brands Corp: Cizzle releases two new Cwench Hydration flavours | 1 | Stockwatch | ||
| 14.01. | Cizzle Brands Corp: Cizzle Brands' Cwench, pasta finds home in USA Lacrosse | 1 | Stockwatch | ||
| 08.01. | Cizzle Brands Corp: Cizzle Brands talks acquisition of Flow Water | 3 | Stockwatch | ||
| 05.01. | Cizzle Brands buys Flow manufacturing assets | 1 | Just Drinks | ||
| 24.12.25 | Cizzle Brands Corp: Cizzle Brands closes Flow Water acquisition | 1 | Stockwatch | ||
| 13.11.25 | Cizzle Brands Corp: Cizzle's Cwench, HappiEats pasta available at Popeye's | 1 | Stockwatch | ||
| CIZZLE BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 05.11.25 | Cizzle Biotechnology - £250,000 Convertible Loan Note Issue | - | RNS | ||
| 05.11.25 | Cizzle Biotechnology - LOI with leading UK Clinical Diagnostic Group | - | RNS | ||
| 30.10.25 | Cizzle Brands Corporation reports Q4 results | 1 | Seeking Alpha | ||
| 02.10.25 | Cizzle Brands Corp: Cizzle rolls out Cwench at Petro-Canada stores | 1 | Stockwatch | ||
| 30.09.25 | Cizzle Biotechnology - Interim Results | - | RNS | ||
| 29.09.25 | Cizzle Biotechnology Holdings: Update on Clinical Laboratory Partnerships in USA | - | RNS | ||
| 22.09.25 | Cizzle Brands unveils sports pasta line: Made with more protein, fiber than standard pasta | 1 | Food Business News | ||
| 18.09.25 | Cizzle Brands Corp: Cizzle Brands' Cwench Hydration available at Loblaw | 2 | Stockwatch | ||
| 10.09.25 | Cizzle Brands Corp: Cizzle Brands launches HappiEats sport pasta | 1 | Stockwatch | ||
| 03.09.25 | Cizzle Brands Corp: Cizzle's Cwench becomes Senators' official sports drink | 1 | Stockwatch | ||
| 21.08.25 | Cizzle Brands Corp: Cizzle's Cwench Hydration in 323 Circle Ks in Ontario | 1 | Stockwatch | ||
| 20.08.25 | Cizzle Brands Corp: Cizzle Brands obtains $5M credit facility from eCapital | 1 | Stockwatch | ||
| 20.08.25 | Cizzle Brands secures $5 million revolving credit facility | 1 | Seeking Alpha | ||
| 18.08.25 | Cizzle Biotechnology - Commercial Progress in USA | 1 | RNS |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,034 | -7,57 % | Medigene: Gericht eröffnet Insolvenzverfahren | Bei Medigene geht die Insolvenz ihren Weg: Das zuständige Amtsgericht in München hat nach Angaben der Gesellschaft vom Freitag heute das Insolvenzverfahren über das Vermögen der Medigene AG sowie der... ► Artikel lesen | |
| NOVAVAX | 8,260 | +1,98 % | Novavax Licenses Matrix-M Adjuvant To Pfizer For Upfront Payment Of $30 Mln | NEW YORK CITY (dpa-AFX) - Novavax, Inc. (NVAX) announced Tuesday that it has entered into a license agreement with Pfizer, Inc. (PFE) for use of Novavax's Matrix-M adjuvant. Under the terms... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,990 | +0,34 % | HEIDELBERG PHARMA AG - Schwäche mit Signalwirkung | ||
| NANOREPRO | 1,540 | -1,91 % | NANOREPRO AG: Ruhige Bewertung nach markanter Schwäche | ||
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| CORE ONE LABS | - | - | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 15,600 | 0,00 % | Palatin Technologies, Inc.: Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Significant progress on multiple fronts - obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement... ► Artikel lesen | |
| AAP IMPLANTATE | 1,530 | 0,00 % | EQS-DD: aap Implantate AG: Deepblue Holding AG, Zeichnung im Rahmen einer Kapitalerhöhung, Privatplatzierung | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
07.01.2026 / 12:01... ► Artikel lesen | |
| CO.DON | 0,017 | -19,51 % | EQS-PVR: CO.DON AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: CO.DON AG
CO.DON AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
07.01.2026 / 12:38 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| BIOXXMED | 0,650 | +7,97 % | XFRA NEW INSTRUMENTS AVAILABLE ON 14.01.2026 | The following instruments on XETRA do have their first trading 14.01.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 14.01.2026
Aktien
1 MHY3130D1013 Heidmar Maritime Hldgs.... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer | SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,280 | +0,79 % | INOVIO Pharmaceuticals, Inc.: FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) | PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| OCUGEN | 1,345 | +0,15 % | Ocugen closes $22.5 million registered direct offering | ||
| CLINUVEL | 6,990 | -0,50 % | Clinuvel Pharmaceuticals Limited: CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies | EXECUTIVE SUMMARY VALLAURIX Research, Development & Innovation Centre to expand its existing facilities and capabilities core focus on accelerating development of liquid long-acting drug delivery... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,310 | -3,28 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease | STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA)... ► Artikel lesen |